These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 36378539)

  • 41. Off-the-Shelf Partial HLA Matching SARS-CoV-2 Antigen Specific T Cell Therapy: A New Possibility for COVID-19 Treatment.
    Kim N; Lee JM; Oh EJ; Jekarl DW; Lee DG; Im KI; Cho SG
    Front Immunol; 2021; 12():751869. PubMed ID: 35003063
    [TBL] [Abstract][Full Text] [Related]  

  • 42. SARS-CoV-2 infection in immunocompromised patients: humoral versus cell-mediated immunity.
    Wei J; Zhao J; Han M; Meng F; Zhou J
    J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32727811
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Real-world evaluation of the impact of two anti-SARS-CoV-2 monoclonal antibody regimens on COVID-19 hospitalizations in older adults.
    Sobolewski KA; Smoke SM; Brophy A; Vassallo AV; Chen B; Hilden P; Patterson R; Pittiglio M; Raja K; Handler E; Freer C
    J Med Virol; 2022 Jun; 94(6):2493-2499. PubMed ID: 35199356
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting.
    Li Z; Xiang T; Liang B; Deng H; Wang H; Feng X; Quan X; Wang X; Li S; Lu S; Yang X; Wang B; Zelinskyy G; Trilling M; Sutter K; Lu M; Dittmer U; Yang D; Zheng X; Liu J
    Front Immunol; 2021; 12():802858. PubMed ID: 35003131
    [TBL] [Abstract][Full Text] [Related]  

  • 45. SARS-CoV-2 neutralizing antibodies for COVID-19: Outcomes for bamlanivimab versus bamlanivimab-etesevimab combination in a racially diverse cohort of patients with significant comorbidities.
    Monday LM; Brar I; Alangaden G; Ramesh MS
    J Clin Pharm Ther; 2022 Sep; 47(9):1438-1443. PubMed ID: 35633095
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Detection of IFNγ-Secreting CD4
    Matyushenko V; Isakova-Sivak I; Kudryavtsev I; Goshina A; Chistyakova A; Stepanova E; Prokopenko P; Sychev I; Rudenko L
    Viruses; 2021 Jul; 13(8):. PubMed ID: 34452355
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Persistence of SARS-CoV-2-specific B and T cell responses in convalescent COVID-19 patients 6-8 months after the infection.
    Sherina N; Piralla A; Du L; Wan H; Kumagai-Braesch M; Andréll J; Braesch-Andersen S; Cassaniti I; Percivalle E; Sarasini A; Bergami F; Di Martino R; Colaneri M; Vecchia M; Sambo M; Zuccaro V; Bruno R; Sachs M; Oggionni T; Meloni F; Abolhassani H; Bertoglio F; Schubert M; Byrne-Steele M; Han J; Hust M; Xue Y; Hammarström L; Baldanti F; Marcotte H; Pan-Hammarström Q
    Med; 2021 Mar; 2(3):281-295.e4. PubMed ID: 33589885
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A Randomized, Placebo-Controlled Clinical Trial of Bamlanivimab and Etesevimab Together in High-Risk Ambulatory Patients With COVID-19 and Validation of the Prognostic Value of Persistently High Viral Load.
    Dougan M; Azizad M; Mocherla B; Gottlieb RL; Chen P; Hebert C; Perry R; Boscia J; Heller B; Morris J; Crystal C; Igbinadolor A; Huhn G; Cardona J; Shawa I; Kumar P; Blomkalns A; Adams AC; Van Naarden J; Custer KL; Knorr J; Oakley G; Schade AE; Holzer TR; Ebert PJ; Higgs RE; Sabo J; Patel DR; Dabora MC; Williams M; Klekotka P; Shen L; Skovronsky DM; Nirula A
    Clin Infect Dis; 2022 Aug; 75(1):e440-e449. PubMed ID: 34718468
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Exploratory data on the clinical efficacy of monoclonal antibodies against SARS-CoV-2 Omicron variant of concern.
    Mazzaferri F; Mirandola M; Savoldi A; De Nardo P; Morra M; Tebon M; Armellini M; De Luca G; Calandrino L; Sasset L; D'Elia D; Sozio E; Danese E; Gibellini D; Monne I; Scroccaro G; Magrini N; Cattelan A; Tascini C; ; Tacconelli E
    Elife; 2022 Nov; 11():. PubMed ID: 36413383
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Editorial: Post-Exposure Prophylactic Neutralizing Monoclonal Antibodies to SARS-CoV-2 for Individuals at High Risk for COVID-19.
    Parums DV
    Med Sci Monit; 2021 Aug; 27():e934393. PubMed ID: 34393218
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Potent SARS-CoV-2-Specific T Cell Immunity and Low Anaphylatoxin Levels Correlate With Mild Disease Progression in COVID-19 Patients.
    Lafon E; Diem G; Witting C; Zaderer V; Bellmann-Weiler RM; Reindl M; Bauer A; Griesmacher A; Fux V; Hoermann G; Miller C; Zabernigg A; Wöll E; Wilflingseder D; Lass-Flörl C; Posch W
    Front Immunol; 2021; 12():684014. PubMed ID: 34194438
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Persistent T cell-mediated immune responses against Omicron variants after the third COVID-19 mRNA vaccine dose.
    Belik M; Liedes O; Vara S; Haveri A; Pöysti S; Kolehmainen P; Maljanen S; Huttunen M; Reinholm A; Lundberg R; Skön M; Österlund P; Melin M; Hänninen A; Hurme A; Ivaska L; Tähtinen PA; Lempainen J; Kakkola L; Jalkanen P; Julkunen I
    Front Immunol; 2023; 14():1099246. PubMed ID: 36756112
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Atrial fibrillation with aberrant ventricular conduction after receiving Bamlanivimab/Etesevimab: a case report.
    Palazzo AG; Zizza A; Nuzzo M; Urciuoli C; Scardia S; Romano A; Guido M; Grima P
    Curr Med Res Opin; 2022 Jul; 38(7):1055-1057. PubMed ID: 35608093
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Adaptive immune responses and cytokine immune profiles in humans following prime and boost vaccination with the SARS-CoV-2 CoronaVac vaccine.
    Wang C; Yang S; Duan L; Du X; Tao J; Wang Y; Yang J; Lv Y; Li J; Zhang C; Wen J; Zhu Y; Chang L; Wang H; Wang Q; Zhao W
    Virol J; 2022 Dec; 19(1):223. PubMed ID: 36550578
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Curbing the Delta Surge: Clinical Outcomes After Treatment With Bamlanivimab-Etesevimab, Casirivimab-Imdevimab, or Sotrovimab for Mild to Moderate Coronavirus Disease 2019.
    Razonable RR; O'Horo JC; Challener DW; Arndt L; Arndt RF; Clune CG; Culbertson TL; Hall ST; Heyliger A; Jackson TA; Kennedy BD; Larsen J; Hanson SN; Sweeten PW; Tulledge-Scheitel SM; Ganesh R
    Mayo Clin Proc; 2022 Sep; 97(9):1641-1648. PubMed ID: 36058578
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Dynamic SARS-CoV-2-specific B-cell and T-cell responses following immunization with an inactivated COVID-19 vaccine.
    Chen Y; Yin S; Tong X; Tao Y; Ni J; Pan J; Li M; Wan Y; Mao M; Xiong Y; Yan X; Yang Y; Huang R; Wu C; Shen H
    Clin Microbiol Infect; 2022 Mar; 28(3):410-418. PubMed ID: 34715346
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Host immunological responses facilitate development of SARS-CoV-2 mutations in patients receiving monoclonal antibody treatments.
    Gupta A; Konnova A; Smet M; Berkell M; Savoldi A; Morra M; Van Averbeke V; De Winter FH; Peserico D; Danese E; Hotterbeekx A; Righi E; ; De Nardo P; Tacconelli E; Malhotra-Kumar S; Kumar-Singh S
    J Clin Invest; 2023 Mar; 133(6):. PubMed ID: 36727404
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Persistent memory despite rapid contraction of circulating T Cell responses to SARS-CoV-2 mRNA vaccination.
    Taus E; Hofmann C; Ibarrondo FJ; Gong LS; Hausner MA; Fulcher JA; Krogstad P; Kitchen SG; Ferbas KG; Tobin NH; Rimoin AW; Aldrovandi GM; Yang OO
    Front Immunol; 2023; 14():1100594. PubMed ID: 36860850
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Immune Memory in Mild COVID-19 Patients and Unexposed Donors Reveals Persistent T Cell Responses After SARS-CoV-2 Infection.
    Ansari A; Arya R; Sachan S; Jha SN; Kalia A; Lall A; Sette A; Grifoni A; Weiskopf D; Coshic P; Sharma A; Gupta N
    Front Immunol; 2021; 12():636768. PubMed ID: 33777028
    [TBL] [Abstract][Full Text] [Related]  

  • 60. An update of antispike severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) monoclonal antibodies.
    Chatterjee S; Choudhury S; Das D
    Indian J Pharmacol; 2022; 54(1):51-57. PubMed ID: 35343208
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.